- Home
- GCMG vs OPT Comparison
GCMG vs OPT Comparison
Compare GCMG & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMG
- OPT
- Stock Information
- Founded
- GCMG 1971
- OPT 1984
- Country
- GCMG United States
- OPT Australia
- Employees
- GCMG N/A
- OPT N/A
- Industry
- GCMG Finance/Investors Services
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GCMG Finance
- OPT Health Care
- Exchange
- GCMG Nasdaq
- OPT Nasdaq
- Market Cap
- GCMG 577.4M
- OPT 574.0M
- IPO Year
- GCMG N/A
- OPT 2020
- Fundamental
- Price
- GCMG $13.28
- OPT $4.41
- Analyst Decision
- GCMG Hold
- OPT Strong Buy
- Analyst Count
- GCMG 5
- OPT 1
- Target Price
- GCMG $13.70
- OPT $12.00
- AVG Volume (30 Days)
- GCMG 317.0K
- OPT 19.4K
- Earning Date
- GCMG 02-11-2025
- OPT 02-26-2025
- Dividend Yield
- GCMG 3.34%
- OPT N/A
- EPS Growth
- GCMG N/A
- OPT N/A
- EPS
- GCMG N/A
- OPT N/A
- Revenue
- GCMG $462,593,000.00
- OPT $261,859.00
- Revenue This Year
- GCMG $16.86
- OPT N/A
- Revenue Next Year
- GCMG $12.95
- OPT $46,864.26
- P/E Ratio
- GCMG N/A
- OPT N/A
- Revenue Growth
- GCMG 8.20
- OPT N/A
- 52 Week Low
- GCMG $8.05
- OPT $1.79
- 52 Week High
- GCMG $13.24
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- GCMG 70.20
- OPT 66.30
- Support Level
- GCMG $12.66
- OPT $3.59
- Resistance Level
- GCMG $13.05
- OPT $3.90
- Average True Range (ATR)
- GCMG 0.30
- OPT 0.26
- MACD
- GCMG 0.06
- OPT 0.06
- Stochastic Oscillator
- GCMG 97.67
- OPT 100.00
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.